from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A phenyltropane drug under development for the treatment of obesity.


Sorry, no etymologies found.


  • Arena Pharmaceuticals Inc. is recruiting about 7,000 patients into three phase III trials to test its antiobesity agent, lorcaserin, while Denmark's NeuroSearch AS is developing tesofensine.

    Drug Makers Seek Antiobesity Blockbuster

  • NeuroSearch reported a slight increase in heart rate and blood pressure among some patients in its tesofensine trials, though it said these effects weren't clinically significant, and Arena said its drug is far more selective than fenfluramine and won't cause the same cardiovascular effects.

    Drug Makers Seek Antiobesity Blockbuster

  • A partner for tesofensine could now be more forthcoming.

    Piggybacking on Orexigen's Unexpected Victory - The Source - WSJ

  • Then there's Neurosearch, whose tesofensine is a highly efficacious obesity project that had completed Phase II but was put on the back burner as the Danish company focused on its lead program in Huntington's disease.

    Piggybacking on Orexigen's Unexpected Victory - The Source - WSJ

  • Rimonabant, brand named Acomplia, is an anti-obesity drug that may help treat addiction, the team noted. 5 or 1 milligram of tesofensine was double that of weight loss seen with the currently available diet drugs Acomplia (rimonabant) or Meridia


  • The group taking .5 milligrams of tesofensine daily lost weight more quickly and kept losing it steadily until the end of the study, at which point the average person had shed about 25 pounds.


  • (The Lancet, Volume 372, Issue 9653, Pages 1906-1913, 29 November 2008) with the conclusion that tesofensine produces a weight loss at least twice that of currently approved anti-obesity drugs.

    American Chronicle

  • The safety data base for tesofensine includes more than 1,500 patients having been exposed to treatment with tesofensine and hereof more than 1,300 on relevant dosing.

    American Chronicle

  • The FDA endorses the overall Phase 3 plan for tesofensine in obesity, including the filing of an NDA based on 12 months safety and efficacy data.

    American Chronicle

  • The main conclusions from the End of Phase II discussions with the FDA include the following: (1) The proposed dose regimen of 0.25 mg or 0.5 mg tesofensine daily in Phase III was endorsed.

    American Chronicle


Log in or sign up to get involved in the conversation. It's quick and easy.